Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Clinical trial NCT05883449 · TERMINATED

Trial details

NCT number: NCT05883449
Sponsor: Affimed GmbH
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory Hodgkin Lymphoma Peripheral T Cell Lymphoma

Start date: 2023-10-10
Primary completion: 2024-11-07
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.